This study showed that RA patients with an inadequate response to conventional DMARDs, including methotrexate, may obtain significant clinical improvement with baricitinib.
Baricitinib has already been submitted for regulatory review in the U.S.2 Baricitinib (Olumiant) was granted marketing authorization in Europe by the European Commission in 2 mg and 4 mg film-coated tablets to treat moderate to severe active RA in adults who have had an inadequate response to, or who are intolerant to, one or more DMARDs.3
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
- Taylor PC, Keystone EC, van der Heidje D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662. doi: 10.1056/NEJMoa1608345
- Eli Lilly and Co. News release: Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo. 2017 Feb 15.
- Eli Lilly and Co. News release: European commission approves once-daily Olumiant tablets for treatment of adults with moderate to severe active rheumatoid arthritis. 2017 Feb 13.